Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Invisible ink could replace permanent tattoos for radiation therapy

NCT ID NCT07095114

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests a special ink called Magic Ink that is only visible under UV light, used to mark the skin for daily radiation treatment in breast cancer patients. The goal is to see if it is as safe and effective as standard permanent tattoo ink, while being less noticeable. Thirty women with early-stage breast cancer will receive the Magic Ink tattoo and be followed for side effects and ease of treatment setup.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Magic Ink (UV-visible tattoo ink)
What this could lead to
If it works, this could make radiation treatment setup easier and less painful, while improving body image by hiding the tattoo marks.
What could go wrong
This is a small early-phase study with only 30 participants, so results may not apply to everyone. The ink might not stay visible or could cause skin reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must have histologically or cytologically confirmed stage 0 ductal carcinoma in situ (DCIS), I, II or III breast cancer and be planning to undergo radiation therapy (RT) after surgery * Participants must be 18 years of age or older * Participant must be able to understand a written informed consent document and be willing to sign it * Participant must be assigned female at birth * Participant must have a Karnofsky performance score of greater than or equal to 70% * Women of child bearing potential must agree to avoid becoming pregnant through defined periods during the course of RT and must meet one of the following: * Surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy * Post-menopausal, defined as no menses for at least 12 months prior to the screening visit without alternative medical causation * Agree to practice true abstinence from sexual intercourse * Not in a sexual relationship in which the may become pregnant (i.e., same-sex relationship) * If they are childbearing potential, agree to use at least one highly effective and at least one additional method of contraception. * For the first six participants only: Participant must have a Fitzpatrick Skin Tone Scale of 5 or 6 Exclusion Criteria: * Participants who have received prior radiation treatment to the affected breast. * Participants with a history of allergic reaction or hypersensitivity attributed to any tattoo ink * Participants with active chronic skin diseases such as psoriasis. Participants with inactive or controlled skin diseases are eligible for this study * Participants that are pregnant or breastfeeding. If a participant wishes to participate in this study, breastfeeding should be discontinued * Participants with a BMI greater than 44.5 as calculated within six months prior to the starting of the study. If there are multiple BMI measurements available in the chart, the most recent will be used to determine eligibility.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ductal carcinoma in situ are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Karmanos Cancer Institute

    RECRUITING

    Detroit, Michigan, 48201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.